First description of revertant mosaicism in familial platelet disorder with predisposition to acute myelogenous leukemia: Correlation with the clinical phenotype

Ana C. Glembotsky; Cecilia P. Marin Oyarzún; Geraldine de Luca; Christophe Marzac; Nathalie Auger; Nora P. Goette; Rosana F. Marta; Hana Raslova; Paula G. Heller

doi:10.3324/haematol.2020.253070

First description of revertant mosaicism in familial platelet disorder with predisposition to acute myelogenous leukemia: Correlation with the clinical phenotype

Ana C. Glembotsky, Cecilia P. Marin Oyarzún, Geraldine de Luca, Christophe Marzac, Nathalie Auger, Nora P. Goette, Rosana F. Marta, Hana Raslova, Paula G. Heller

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

7 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	535-539
Nombre de pages	5
journal	Haematologica
Volume	105
Numéro de publication	10
Les DOIs	https://doi.org/10.3324/haematol.2020.253070
état	Publié - 1 oct. 2020

Accès au document

10.3324/haematol.2020.253070

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Glembotsky, A. C., Marin Oyarzún, C. P., de Luca, G., Marzac, C., Auger, N., Goette, N. P., Marta, R. F., Raslova, H., & Heller, P. G. (2020). First description of revertant mosaicism in familial platelet disorder with predisposition to acute myelogenous leukemia: Correlation with the clinical phenotype. Haematologica, 105(10), 535-539. https://doi.org/10.3324/haematol.2020.253070

@article{b18959a038694ad1af70266f0c3ed5c5,

title = "First description of revertant mosaicism in familial platelet disorder with predisposition to acute myelogenous leukemia: Correlation with the clinical phenotype",

author = "Glembotsky, {Ana C.} and {Marin Oyarz{\'u}n}, {Cecilia P.} and {de Luca}, Geraldine and Christophe Marzac and Nathalie Auger and Goette, {Nora P.} and Marta, {Rosana F.} and Hana Raslova and Heller, {Paula G.}",

note = "Funding Information: Funding: this study was supported by grants from the Fondation Nelia et Amadeo Barletta (to PH, 2017), the Ligue Nationale Contre le Cancer ({\'e}quipe labellis{\'e}e 2019 to HR) and the cooperation program between France and Argentina, Ecos-Sud-Ministerio de Ciencia, Tecnolog{\'i}a e Innovaci{\'o}n Productiva (MINCyT) (to HR and PH, 2016). CMO was supported by a postdoctoral fellowship from the Fondation Nelia et Amadeo Barletta and from the Fondation de la Recherche M{\'e}dicale. Correspondence: PAULA G. HELLER - [email protected] doi:10.3324/haematol.2020.253070",

year = "2020",

month = oct,

day = "1",

doi = "10.3324/haematol.2020.253070",

language = "English",

volume = "105",

pages = "535--539",

journal = "Haematologica",

issn = "0390-6078",

number = "10",

}

Glembotsky, AC, Marin Oyarzún, CP, de Luca, G, Marzac, C, Auger, N, Goette, NP, Marta, RF, Raslova, H & Heller, PG 2020, 'First description of revertant mosaicism in familial platelet disorder with predisposition to acute myelogenous leukemia: Correlation with the clinical phenotype', Haematologica, VOL. 105, Numéro 10, p. 535-539. https://doi.org/10.3324/haematol.2020.253070

First description of revertant mosaicism in familial platelet disorder with predisposition to acute myelogenous leukemia: Correlation with the clinical phenotype. / Glembotsky, Ana C.; Marin Oyarzún, Cecilia P.; de Luca, Geraldine et al.
Dans: Haematologica, Vol 105, Numéro 10, 01.10.2020, p. 535-539.

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

TY - JOUR

T1 - First description of revertant mosaicism in familial platelet disorder with predisposition to acute myelogenous leukemia

T2 - Correlation with the clinical phenotype

AU - Glembotsky, Ana C.

AU - Marin Oyarzún, Cecilia P.

AU - de Luca, Geraldine

AU - Marzac, Christophe

AU - Auger, Nathalie

AU - Goette, Nora P.

AU - Marta, Rosana F.

AU - Raslova, Hana

AU - Heller, Paula G.

N1 - Funding Information: Funding: this study was supported by grants from the Fondation Nelia et Amadeo Barletta (to PH, 2017), the Ligue Nationale Contre le Cancer (équipe labellisée 2019 to HR) and the cooperation program between France and Argentina, Ecos-Sud-Ministerio de Ciencia, Tecnología e Innovación Productiva (MINCyT) (to HR and PH, 2016). CMO was supported by a postdoctoral fellowship from the Fondation Nelia et Amadeo Barletta and from the Fondation de la Recherche Médicale. Correspondence: PAULA G. HELLER - [email protected] doi:10.3324/haematol.2020.253070

PY - 2020/10/1

Y1 - 2020/10/1

UR - http://www.scopus.com/inward/record.url?scp=85092303420&partnerID=8YFLogxK

U2 - 10.3324/haematol.2020.253070

DO - 10.3324/haematol.2020.253070

M3 - Article

C2 - 33054100

AN - SCOPUS:85092303420

SN - 0390-6078

VL - 105

SP - 535

EP - 539

JO - Haematologica

JF - Haematologica

IS - 10

ER -